Company intelligence / Profile preview

PeptiMed

Madison, Wisconsin, United Statescbinsights.com ↗

Ownership: Private
Development stage: Preclinical

Overview

PeptiMed develops potent siRNA molecules to down-regulate oncogene targets such as EVI1 for the treatment of multiple cancers. The company has partnered with the National Cancer Institute to assess the safety of its proprietary nanoparticle drug delivery system. No published clinical results are available yet; programs appear to be in preclinical or IND-enabling stages

Therapeutic areas: Oncology
Modalities: siRNA (small interfering RNA)nucleotide-based therapies
Industry: Biotech

Drug pipeline

1 asset

EVIRNA/hELP

Pre-clinical

Indications: Cancer

Partnerships

National Cancer Institute (NCI), for assessment of drug delivery nanoparticle formulations

Beyond the preview

Go deeper on PeptiMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PeptiMed.

Explore the full profile